2017N347248_00 CONFIDENTIA L
GlaxoSmithKline group of companies 206874
1TITLE PA GE
Protocol Title: A single centre, open label, one sequence, cross- over study  to evaluate 
the effect of itraconazole on the pharmacokinetics of single inhaled doses of nemiralisib 
in healthy  subjects.
Protocol Number : 206874
Short Title : A study  to evaluate the effect of itraconazole on the PK of nemiralisib
Compound Number: GSK2269557
Sponsor Name and Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Medical Monitor Name and Contact Information can be found in the Study 
Reference Manual
Regulatory Agency Identifying Number(s): IND Number 125676
Approval Date: 12-DEC - 2017
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised c opying or use of this information is prohibited. 2018N365720_00
 
P P D 2 0 1 8 N 3 6 5 7 2 0 _ 0 0 
P P D 
2017N347248_00 CONFIDENTIA L
206874
3TABLE OF CONTENTS
PAGE
1.SYNOPSIS ............................................................................................................... 5
2.SCHEDULE OF ACTIVITI ES (SOA) ......................................................................... 7
3.INTRODUCTION .................................................................................................... 11
3.1. Study Rationale .......................................................................................... 11
3.2. Background ................................................................................................ 11
3.3. Benefit/Risk Assessment ............................................................................ 12
3.3.1. Risk Assessment ......................................................................... 13
3.3.2. Benefit Assessment ..................................................................... 15
3.3.3. Overall Benefit:Risk Conclusion ................................................... 15
4.OBJECTIVES AND ENDPO INTS ........................................................................... 15
5.STUDY DESIGN .................................................................................................... 15
5.1. Overall Design ............................................................................................ 15
5.2. Number of Participants ............................................................................... 17
5.3. Participant and Study Completion ............................................................... 17
5.4. Scientific Rationale for Study Design .......................................................... 17
5.5. Dose Justification ........................................................................................ 18
6.STUDY POPULATION ........................................................................................... 19
6.1. Inclusion Criteria ......................................................................................... 19
6.2. Exclus ion Criteria ........................................................................................ 20
6.3. Lifestyle Restrictions ................................................................................... 21
6.3.1. Meals and Dietary Restrictions .................................................... 21
6.3.2. Caffeine, Alcohol, and Tobacco ................................................... 22
6.3.3. Activity ......................................................................................... 22
6.4. Screen Failures ........................................................................................... 22
7.TREATMENTS ....................................................................................................... 23
7.1. Treatments Administered ............................................................................ 23
7.2. Dose Modification ....................................................................................... 23
7.3. Method of Treatment Assignment ............................................................... 24
7.4. Blinding ....................................................................................................... 24
7.5. Preparation/Handling/Storage/Accountability .............................................. 24
7.6. Treatment Compliance................................................................................ 24
7.7. Concomitant Therapy .................................................................................. 24
7.8. Treatment after the End of the Study .......................................................... 25
8.DISCONTINUATION CRIT ERIA ............................................................................. 26
8.1. Discontinuation of Study Treatment ............................................................ 26
8.1.1. Liver Chemistry Stopping Criteria ................................................ 26
8.1.2. QTc Stopping Criteria .................................................................. 26
8.1.3. FEV 1stopping criteria .................................................................. 27
8.1.4. Other study stopping criteria ........................................................ 27
8.1.5. Temporary Discontinuation .......................................................... 27
8.1.6. Rechallenge ................................................................................. 27
8.1.6.1. Study Treatment Restart or Re -challenge ................... 27 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
48.2. Withdrawal from the S tudy.......................................................................... 27
8.3. Lost to Follow Up ........................................................................................ 28
9.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 28
9.1. Efficacy Assessments ................................................................................. 29
9.2. Adverse Events ........................................................................................... 29
9.2.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 29
9.2.2. Method of Detecting AEs and SAEs ............................................. 30
9.2.3. Follow -up of AEs and SAEs ......................................................... 30
9.2.4. Regulatory Reporting Requirements for SAEs ............................. 30
9.2.5. Pregnancy ................................................................................... 30
9.3. Treatment of Overdose ............................................................................... 31
9.4. Safety Assessments ................................................................................... 31
9.4.1. Physical Examinations ................................................................ .31
9.4.2. Vital Signs .................................................................................... 32
9.4.3. Electrocardiograms ...................................................................... 32
9.4.4. Spirometry ................................................................................... 32
9.4.5. Clinical Safety Laborator y Assessments ...................................... 32
9.5. Pharmacokinetics ....................................................................................... 33
9.6. Pharmacodynamics .................................................................................... 33
9.7. Genetics ..................................................................................................... 33
9.8. Biomarkers ................................................................................................ .33
9.9.Health Economics OR Medical Resource Utilization and Health 
Economics .................................................................................................. 33
10.STATISTICAL CONSIDER ATIONS ........................................................................ 34
10.1. Sample Size Determination ........................................................................ 34
10.1.1. Sample Size Se nsitivity ................................................................ 35
10.2. Populations for Analyses ............................................................................ 35
10.3. Statistical Analyses ..................................................................................... 35
10.3.1. Pharmacokinetic Analyses ........................................................... 36
10.3.2. Safety Analyses ........................................................................... 36
10.3.3. Interim Analyses .......................................................................... 37
11.REFERENCES ....................................................................................................... 38
12.APPENDICES ........................................................................................................ 39
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 39
12.2. Appendix 2: Clinical Laboratory Tests ......................................................... 41
12.3. Appendix 3: Study Governance Considerations .......................................... 43
12.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluati ng, Follow -up, and Reporting ....................................... 47
12.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 52
12.6. Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 55 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
51. SYNOPSIS
Protocol Title: A single centre, open label, one sequence, cross- over study  to evaluate 
the effect of itraconazole on the pharmacokinetics of single inhaled doses of nemiralisib 
in healthy  subjects.
Short Title: A stu
dy to evaluate the effect of itraconazole on the PK of nemiralisib
Rationale:
The in vitro Cytochromes P450 ( CYP )phenoty ping study  and in vitro inhibition data 
indicate CYP3A4 may  be the major route of clearance for nemiralisib. Therefore, the co -
administ ration of drug therapies which modulate CYP3A4 (specificall y CYP3A4 
inhibitors) may  alter the exposure of nemiralisib (i.e. increase in exposure). Current 
recommendations b y regulatory  agencies Food and Drug Administration ( FDA )and 
European Medicines Agen cy (EMA) specify  that “ when metabolism is a significant 
pathway (i.e. constitutes 25% or more of the drug’s overall elimination) in vivo studies 
using appropriate inhibitor(s)/inducer(s) are warranted ”. In line with recommendations, 
this clinical drug inte raction study  with itraconazole (a potent CYP3A4 inhibitor) is 
required. Ongoing and future clinical studies using nemiralisib will use the data generated 
from this current stud y to justify  inclusion / exclusion criteria based on concomitant 
medications wh
ich affect CYP3A4 and potentially inform dose modification in case of 
co-administration with medication affecting CYP3A4 activity .
Objectives and Endpoints:
Objectives Endpoints
Primary
To characterize the effect of repeat oral 
dosing of itraconazole on the 
pharmacokinetics of a single inhaled 
dose of nemiralisib in healthy subjects AUC(0 -∞), AUC(0 -t), Cmax, tmax , t 1/2
Secondary
To investigate the safety and tolerability 
of single inhaled dose of nemiralisib, when 
dosed alone and concomitantly with 
itraconazole, in healthy subjects
To investigate the pharmacokinetics of 
itraconazole and hydroxy -itraconazole 
when co -administered with nemiralisibAdverse events (AE), clinical laboratory 
values, vital signs, electrocardiogram 
(ECG) and spirometry
AUC(0 -∞), AUC(0 -t), Cmax, tmax, t 1/2
AUC(0 -∞)Area under the concentration -time curve from time zero (pre -dose) extrapolated to infinite time , AUC(0 -t):
Area under the plasma concentration versus time curve from time zero to t , Cmax; maximum observed plas ma 
concentration, tmax : time to Cmax, t 1/2:  Terminal phase half -life 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
6Overall Design:
This is a Phase I, single centre, open label, one sequence cross -over study  to be 
conducted in healthy  male s and females of non- child bearing potential. The study  will 
evaluate the Pharmacokinetic ( PK)
, safet y and tolerability of nemiralisib when 
administered alone and when administered concomitantly  with repeat doses of 
itraconazole, a known strong inhibitor of CYP3A4, to simulate a steady -state exposure of 
itraconazole . 
The pharmacokinetics of itraconazole and h ydrox y-itraconazole (its h ydroxy -metabolite) 
will be assessed to provide precise estimates of its pharmacokinetics to validate and 
support any  interaction observed with nemiralisib as well as future usage via insilico
modelling for nemiralisib and other drugs.  
Number of Participant s:
Approximately  20 participants will be enrolled such that approximately  16 evaluable 
participants complete the study . 
Treatment Groups and Duration:
Each participant will particip ate in the study  for approximately 7weeks. They  will 
complete a screening visit, 2 treatment periods (nemiralisib alone followed by  nemiralisib 
co-administered with itraconazole), and a follow up visit. 
Screening : 
Participants must be screened within 21 days before the first dose (Day  1), and must meet 
all eligibility  criteria.  
Period 1:
-Participants will be admitted to the clinical research unit on Day  -1 and will 
remain in -house until collection of the final PK sample on Day  6. 
-On Day  1, participant s will receive a single dose of 100 mcg nemiralisib. 
Period 2:
-There will be a washout of at least 14 day s between the administration of 
nemiralisib in Period 1 and the administration of nemiralisib in Period 2. 
-Participants will be admitted to the clin ical research unit on Day  -1 and will 
remain in -house until collection of the final PK sample on Day  11. 
-From Day  1 to 10 inclusive, participants will receive a single dose of 200 mg 
itraconazole in the morning. 
-On Day  5, participants will receive a sing le dose of 100 mcg nemiralisib one hour 
after the dose of 200 mg itraconazole.
Follow -
up:
Participants will be instructed to return for a follow- up visit 5 -10 day s after the last
dose of itraconazole. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
72. SCHEDULE OF ACTIVITI ES (SOA )
Table 1 Screening and Follo w-up
ProcedureScreening (up to 21 days 
before Day 1)Follow -up (within 5 −10 days of 
last dose itraconazole )Notes
Informed consent X
Demography X
Inclusion and exclusion criteria X
Past and current medical conditions  X
Medical history (includes substance usage) X Substances: Drugs, Alcohol, tobacco and caffeine
Physical examin ation X XFull examination (including height and weight) at 
screening, brief examination at follow -up
Vital signs X Triplicate 
12-lead ECG X X Triplicate 
FEV 1and FVC X Triplicate
Laboratory a ssessments (hemat ology and clinical 
chemistry)X X
Urinalysis X
HIV, Hepatitis B and C screening XIf test otherwise performed within 3 months prior to 
first dose of study treatment, testing at screening is 
not required
Alcohol breath test & drug screen X Includes urine cotinine test
SAE review X X
AE review X
ECG: Electrocardigram, FEV1: Forced expiratory volume in 1 second, FVC: Forced vital capacity, HIV: Human immunodeficiency vi rus, AE: Adverse event, SAE: Serious adverse event. 
 
 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
8Table 2 Period 1
ProcedureTreatment Period Days Notes
–1 1 2 3 4 5 6
Admission X
Discharge X
Alcohol breath test & drug screen X Includes urine cotinine test
Laboratory a ssessments (hematology, clinical 
chemistry and urinalysis)X XDay −1 results to be reviewed before dosing on Day 1
Brief physical examination X X
Inhaler ( ElliptaTM) training XTraining conducted by reviewing the Patient Information Leaflet with 
the participant . Additional training may be conducted at the discretion 
of the investigator.
FEV 1 X Triplicate.
12-lead ECG X X Single measurement. Pre -dose on Day 1.
Vital signs X X Single measurement. Pre -dose on Day 1.
Study treatment (nemiralisib) X
Pharmacokinetic ( PK)(nemiralisib) X X X X X Xpre-dose, and 5 min, 30 min, 2 h , 6 h, 12h, 24 h, 48 h, 72 h, 96 h 
and 120 h post- dose 
AE review ============================== 
SAE review X============================== 
Concomitant medication review X============= =================  
 
 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
9Table 3 Period 2
ProcedureTreatment Period Days Notes
–1 1 2 3 4 5 6 7 8 9 10 11
Admission X
Discharge X
Alcohol breath test & drug screen X Includes urine cotinine tes t
Brief physical examination X X
Laboratory a ssessments 
(hematology, clinical chemistry and 
urinalysis )X XPre-dose at all timepoints. Day −1 results to be 
reviewed before dosing on Day 1. 
Clinical chemistry only X X X XPre-dose at all timepoints. Day 4 results to be reviewed 
before itraconazole dosing on Day 5.
12-lead ECG X X X X X XSingle measurement. Pre -dose and 3h post- dose 
(itraconazole) on Day 1. P re-dose at all other 
timepoints, Day 4 results to be reviewed before 
itraconazole dosing on Day 5.
Vital signs X X X X X X Single measurement. Pre -dose at all timepoints
Study treatm ent (itraconazole) X X X X X X X X X X Approx. 1 h post standard meal. 
FEV 1 X Triplicate
Inhaler (Ellipta) training XTraining conducted by reviewing the Patient Information 
Leaflet with the participant . Additional training may be 
conducted at the discretion of the investigator. 
Study treatment (nemiralisib) X 1h post itraconazole administration.
PK (nemiralisib) X X X X X X Xpre-dose, and 5 min, 30 min, 2 h, 6 h, 12 h, 24 h, 48 h, 
72h, 96 h, 120 h and 144 hpost- dose (nemiralisib) 
 
 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
10ProcedureTreatment Period Days Notes
–1 1 2 3 4 5 6 7 8 9 10 11
PK (itraconazole + hydroxy -
itraconazole)X X XPre-dose, 30 min, 1 h, 1.5 h, 2h, 3h,4h, 6h,8h,12h 
post- dose (itraconazole) on Day 1
Pre-dose, 30 min, 1 h, 1.5 h, 2h, 3h,4h, 6h,8h, 12 h 
and 24 h hours post- dose (itraconazole) on Day 5
AE review ================================================== 
SAE review X================================================== 
Concomitant medication review X================================================== 
The timing and number of planned study  assessments, including safet y and pharmacokinetic assessments may  be altered during 
the course of the study  based on newl y available data (e.g., to obtain data closer to the time of peak plasma concentrations) to 
ensure a ppropriate monitoring. 
Any changes in the timing or addition of time points for any  planned stud y assessments must be documented and approved by 
the relevant stud y team member and then archived in the sponsor and site study files, but will not constitute a protocol 
amendment. The Institutional review board ( IRB
)/Independent ethics committee ( IEC)willbe informed of an y safet y issues that 
require alteration of the safet y monitoring scheme or amendment of the Informed consent form ( ICF). 
 
 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
113. INTRODUCTION
3.1. Stud y Rationale
The in vitro CYP phenoty ping study  and in vitro inhibition data indicate CYP3A4 may  be 
the major route of clearance for nemiralisib (Investigator’s Brochure [ GlaxoSmithKline 
Document Number 2012N141231_08]) . There fore, the co -administration of drug 
therapies which modulate CYP3A4 (specifically  CYP3A4 inhibitors) may alter the 
exposure of nemiralisib (i.e. increase in exposure) . Current recommendations by  
regulatory  agencies Food and Drug Administration ( FDA )and European Medicines 
Agency  (EMA ) ([EMA ,2012], [ FDA ,2017]) specify  that “ when metabolism is a 
significant pathway (i.e. constitutes 25% or more of the drug’s overall elimination) in 
vivo studies using appropriate inhibitor(s)/inducer(s) are warranted ”. In line with 
recommendations, this clinical drug interaction study  with itraconazole (a potent
CYP3A4 inhibitor) is required . Ongoing and future clinical studies using nemiralisib will 
use the data generated from this current study  to justify  inclusion / exclusion criteria
based on concomitant medications which affect CYP3A4 and potentially  inform dose 
modification in case of co -administration with medication affecting CYP3A4 activity .
3.2.
Backg round
Nemiralisib (also known as GSK2269557) is a potent and highl y selective inhaled 
phosphoinositide 3
-kinase (PI3K) -delta ( ) inhibitor, being developed as an anti-
inflammatory  agent for the treatment of Chronic obstructive pulmonary  disease (COPD )
and other inflammatory lung disease such as asthma and bronchiectasis.  PI3K is a 
member of the Class IA family  of PI3Ks, that converts the membrane phospholipid 
phosphatidy linositol 4,5 -biphosphate (PI P2) into phosphatidy linositol 3,4,5- trisphosphate 
(PIP3).  PI P3 is a second messenger in many  cellular processes including cell growth, 
differentiation and migration. 
PI3Khas specific roles in mediating antigen receptor and cy tokine signalling in T -cells, 
mast cells and B -cells.PI3Kis thought to play  an important part in various epithelial 
responses relevant for the development of COPD, asthma and bronchiectasis. Chronic 
treatment with antibiotics such as macrolides isincreasingl y used in these conditions to 
prevent exacerbations. Since macrolides, and oth er drugs used to treat co- morbidities 
associated with these conditions, are CYP3A4 inhibitors it is important to ensure that co -
administration of these drugs do esnot substantially  alter sy stemic nemiralisib levels. 
Hence ,in this study  the sy stemic pharma cokinetics of nemiralisib will be examined with 
the co- administration of itraconazole, a strong CYP3A4 inhibitor
Nemiralisib has alread y been administered as a nebulised solution and dry powder 
formulation in single and repeated doses to healthy  subjects a nd patients with asthma and 
COPD, and has been well tolerated across the range of doses used.   Adetailed description 
of the chemistry , pharmacology , efficacy , and safety  of nemiralisib is provided in the 
Investigator’s Brochure [ GlaxoSmithKline Document Number 2012N141231_08
]. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
123.3. Benefit/Risk A ssessment
More detailed information about the known and expected benefits and risks and 
reasonabl y expected adverse events of nemiralisib may  be found in the Investigator’s 
Brochure [Glax oSmithKline Document Number 2012N141231_08].
More detailed information about the known and expected benefits and risks and 
reasonabl y expected adverse events of itraconazole may be found in the FDA label
(Itraconazole Prescribing I nformation , 2010 ). 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
133.3.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational P roduct (IP)
Bronchospasm Can potentially occu r with any inhaled treatment. All doses of study treatment will be administered 
in the clinical pharmacology unit in the presence 
of trained clinical staff. 
Treatment with a short -acting inhaled 
bronchodilator will be available and administered 
as appropr iate and determined by the 
Investigator. Participants will receive no more 
nemiralisib treatment and may be withdrawn 
from the study.
Mucosal irritancy Detected in 13 week toxicology study in the dog. Participants will be regularly monitored for AEs. 
No evidence of mucosal irritancy has been seen 
so far in clinical studies.
Itraconazole administration The most common Adverse Drug Reactions 
associated with the administration of itraconazole 
are: 
-Upper respiratory tract infections
-Increased hepatic enzymes
- H ypoacusis
- H eadache
- Abdominal pain
- D iarrheaOnly healthy participants will be allowed to 
participate in the proposed study.
Exclusion criteria, close monitoring of clinical 
parameters and a dverse events will be 
conducted. S topping criteria will be utilis ed to 
mitigate a nd assess cardiovascular and liver 
effects. 
 
 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
14Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
-Nausea
- F atigue
- A rrhythmia
- C ough
- S ore throat
-Back pain 
Refer to the FDA label (Itraconazole Prescribing 
Information , 2010 ) for itraconazole for the full lis t 
of Adverse Drug Reactions. 
 
 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
153.3.2. Benefit A ssessment
Health y participants in this study  will receive no direct medical benefit.  They  may  
however benefit from the thorough medical assessments they  receive during the course of 
the study .
3.3.3. Overal l Benefit:Risk Conclusion
It is considered acceptable to conduct this study  in healthy  participants, because whilst 
they will receive no direct medical benefit, the risks from the study  treatment and 
procedures are minimal.  The study  will be conducted in a fully  equipped clinical 
pharmacology  unit with access to hospital emergency  facilities.
4. OBJECTIVES A ND ENDPO INTS
Objectives Endpoints
Primary
To characterize the effect of repeat oral 
dosing of itraconazole on the 
pharmacokinetics of a single inhaled
dose of nemiralisib in healthy 
participant s  AUC(0 -∞), AUC(0 -t), Cmax, tmax , t1/2
Secondary
To investigate the safety and tolerability 
of single inhaled dose of nemiralisib, when 
dosed alone and concomitantly with 
itraconazole, in healthy participants
To investigate the pharmacokinetics of 
itraconazole and hydroxy -itraconazole 
when co -administered with nemiralisibAdverse events (AE), clinical laboratory 
values, vital signs, electrocardiogram 
(ECG) and spirometry
AUC(0 -∞), AUC(0 -t), Cmax, tmax , t1/2
AUC(0 -∞)Area under the concentration -time curve from time zero (pre -dose) extrapolated to infinite time , AUC(0 -t):
Area under the plasma concentration versus time curve from time zero to t , Cmax; maximum observed plasma 
concentration, tmax : time to Cm ax, t 1/2:  Terminal phase half -life
5. STUDY DESIGN
5.1. Overall Design
This is a Phase I, single centre , open label , one sequence cross -over study  to be 
conducted in healthy  male s and females of non-child bearing potential . The study  will 
evaluate the PK, safet y and tolerability of nemiralisib when administered alone and when  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
16administered concomitantly  with repeat doses of itraconazole, a known strong inhibitor of 
CYP3A4, to simulate a stead y-state exposure of itraconazole . 
The pharmacokinetics of itracon azole and hydroxy-itraconazole (its h ydroxy -metabolite)
will be assessed to provide precise estimates of its pharmacokinetics to validate and 
support any  interaction observed with nemiralisib as well as future usage via in silico
modelling for nemiralisib and other drugs .  
Each participant will participate in the study  for approximately 7 weeks. They  will 
complete a screening visit, 2 treatment periods (nemiralisib alone followed by  nemiralisib 
co-administered with itraconazole) , and a follow up visit (see Figure 1).  
Figure 1 Overall study  schematic
Screening : 
Participants must be screened within 21 day s before the first dose (Day  1), and must meet 
all eligibility  criteria.  
Period 1:
-Participants will be a dmitted to the clinical research unit on Day  -1 and will 
remain in -house until collection of the final PK sample on Day  6. 
-On Day  1, participants will receive a single dose of 100 mcg nemiralisib. 
Period 2: 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
17-There will be a washout of at least 14 days be tween the administration of 
nemiralisib in Period 1 and the administration of nemiralisib in Period 2. 
-Participants will be admitted to the clinical research unit on Day  -1 and will 
remain in -house until collection of the final PK sample on Day  11. 
-From Day 1to 10 inclusive, participants will receive a single dose of 200 mg 
itraconazole in the morning. 
-On Day  5, participants will receive a single dose of 100 mcg nemiralisib one hour 
after the dose of 200 mg itraconaz ole.
-Participants will receive the ad ministration of nemiralisib on Day  5 and 
itracon
azole doses on Day 5to Day 10 onl y if there are no findings that are 
considered clinically  significant by  the Investigator ( in consultation with the 
medical monitor if needed) during review of Day 4 clinical chemistry  and ECG.
-Itraconazole will be administered at approximately the same time every  day and 
approximately  1 h after a standard breakfast .
-Nemiralisib will be administered at approximately the same time in Period 1 and 
in Period 2. 
Follow -up:
Partic ipants will be instructed to return for a follow -up visit 5 -10 day s after the last
dose of itraconazole .
5.2. Number of Participants
Approximat ely 20participants will be enrolled such that approximately  16evaluable 
participants complete the study . Evaluable p articipants are those who have at least one 
nemiralisib PK sample taken in both periods 1 and 2, and have completed dosing up to 
the point of any  withdrawal.
If participants prematurely  discontinue the study , additional replacement participants may 
be recr uited a t the discretion of the Sponsor.
5.3. Participant and Study  Completion
A participant is considered to have completed the study  if he/she has completed all 
phases of the stud y including the last visit.
The end of the stud y is defined as the date of the la st visit forthe last participant in the 
study .
5.4. Scientific Rationale for Study  Design
This is a drug -drug interaction study  in health y male s
and females of non- child bearing 
potential . Participants will be dosed with nemiralisib before and during co -admini stration 
ofitraconazole and will act as their own control.
A sufficient wash -out period is included 
(at least 14- days between nemiralisib dose administrations in Period 1 and in Period 2) to 
remove an y effect or residual sy stemic exposure from the first dose of nemiralisib before 
starting itraconazole dose administration in Period 2 .  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
18An open label design was considered appropriate because the primary  objective 
(pharmacokinetic parameters) does not require blinding and no pharmacody namic 
markers were inclu ded in the study . 
Woman of child bearing potential areexcluded from participation in this study  because 
itraconazole has shown reproduction toxicity  in animal studies. In addition, t here is 
limited information on the use of itraconazole during pregnancy  and during post -
marketing experience, cases of congenital abnormalities have been reported.
5.5. Dose Justification
The chosen dose level of nemiralisib in this study  is 100 mcg delivered via the Ellipta 
device. This dose level has been chosen as it is within the current dose range chosen for 
investigation in the ongoing phase 2b study  200879 (50 to 750 mcg) and has previously  
demonstrated an adequately  characterizable PK profile . The optimal efficacious dose is 
currentl y unknown but in a previous clinical stud yin patients (study  PII116678 in 
exacerbating COPD patients) dosed at 1000 mcg/day  (equivalent to 500 mcg using the 
Ellipta device and the formulation proposed in this Drug drug interaction [ DDI]study ) a 
positive primary  endpoint was achieved (airway  volu me as measured b y functional CT 
imaging). The 100 mcg dose level will 
provide an adequate exposure margin over pre -
clinical exposure stopping criteria (based on toxicology  No observed adverse event level 
[NOAEL ]and toxicokinetics) should the exposure to n emiralisib increase significantly
when co -administered with a CYP3A4 inhibitor . Using the predicted exposure of 
nemiralisib at 100 mcg in humans (extrapolated exposures of 0.41 ng/mL and 1.2 
ng.h/mL for Cmax and AUC 24respectively) and using the 13 week do g NOAEL  
exposures (680 ug/kg/day NOAEL on week 13 for male and female combined of 21 
ng/mL and 79 ng.h/mL respectivel y) gave margins of approximately  51-fold and 6 6-fold 
for Cmax and AUC 24respectivel y. These margins are considered to provide sufficient 
coverfor any  potential increase in nemiralisib expos ures that co -administration of 
itraconazole would be anticipated to cause. The analy tical assay  for nemiralisib and the 
known exposure range over the proposed sampling regimen is deemed appropriate to 
fully characterise the profile out to 120 hours post dose in Period 1 and 144 hours post 
dose in Period 2, following a 100 mcg single dose. Preliminary  data from an ongoing trial 
(207674 PK bridge study single doses phase 2b material) defined terminal eliminat ion 
half-life to be approximately  40 hours with a Tmax observed in the sample taken 
immediately  post dose (5 mins) which fell off rapidly  in a biexponential manner. The 
long elimination half -life of nemiralisib is the driver behind the length of the sampli ng 
regimen. Nemiralisib is also an in vitro inhibitor of CYP3A4 (Ki of 4.2 µM [GSK report 
reference 2017N345216_00 ]) however as s ystemic concentrations are likel y to be < 3 nM 
(1 ng/mL) following a single inhaled dose of onl y 100 µg the inhibition is predicted to be 
negligible.  
The ty pical adult dose of itraconazole is 200 mg for up to 12 weeks although intermittent 
usage can be up to 400 mg/day . Itraconazole dosing of 200 mg once dail y for 5 days prior 
to the concomitant vic tim (nemiralisib) dose will enable the victim interaction to be 
observed on a background of stead y state exposure and similar to that seen in clinical 
practise [ Ke, 2014]. A more recent publication describing the best pra ctices around the 
use of itraconazole as a potent CYP3A4 inhibitor in DDI studies recommends at least a 3  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
19day lead -in with co- administration of the victim compound on Day  4 [Liu, 2016 ]. 
Maximum inhibition was also seen i f the victim drug was given one hour after 
itraconazole administration [ Ke, 2014]. I traconazole administration will continue after 
the dose of nemiralisib to ensure that inhibition is maintained throughout the elimination
phase of nemiralisib.
6. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrolment criteria, also 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be included in the st udy onl y if all of the following criteria 
apply :
Age
1.Participant must be 18 to 75 y ears of age inclusive, at the time of signing the 
informed consent.
Type of Participant and Disease Characteristics
2.Participants who are overtly  health y as determined by medical evaluation including 
medical history , phy sical examination, laboratory  tests, and cardiac evaluation .
3.Normal spirometry  at Screening (FEV 1and FVC ≥80% of predicted. Predicted 
values will be based upon [ Quanjer , 2012]. Measure ments to be taken in triplicate. 
The highest value of each individual component must be ≥80% of predicted).
4.A participant with a clinical abnorm ality or laboratory parameter(s) (except for liver 
function tests) outside the reference range for the population being studied may  be 
included only  if the investigator, in consultation with the medical monitor if needed, 
agree and document that the findin g is unlikely to introduce additional risk factors 
and will not interfere with the study procedures.
Weight
5.Body weight >50 kg and body mass index (BMI) within the range 18.0 –35.0 kg/m2 
(inclusive).
Sex
6.Male and/or female
a.Male participants:
A male partic ipant must agree to use contraception as detailed in 
Appendix 5of this 
protocol during the treatment period and for at least 10 day s after the last dose of 
study  treatment and refrain from donating sperm during this period.
b.Female participants:  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
20A female participant is eligible to participate if she is not pregnant (see Appendix 5), 
not breastfeeding, and not a woman of childbearing potential (WOCBP) as defined in 
Appendix 5.
Informed Consent
7.
Capable of giving signed informed consent as described in Appendix 3 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (I CF) and in this protocol.
6.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.History  or presence of cardiovascular, respiratory  (except childhood asthma, which 
has now remitted), hepatic, renal, gastrointestinal, endocrine, hematological, 
psychiatric or neurological disorders capable of significantly  altering the absorption, 
metabolism, or elimination of drugs; constituting a risk when taking the study  
treatment; or interfering wit h the interpretation of data 
2.Abnormal blood pressure [as determined by  the investigator]
3. Liver function test results above the upper limit of normal (ULN)
4.Current or chronic history of liver disease, or known hepatic or biliary  abnormalities 
(with the exc eption of Gilbert's s yndrome or as ymptomatic gallstones)
5.QTcF>450 msec 
Prior/Concomitant Therapy
6.Past or intended use of over -the-counter or prescription medication including herbal 
medications within 14days prior to dosing ( Specific medications listed in Section 
7.7may be allowed)
Prior/Concurrent Clinical Study Experience
7.
Participation in the study would result in loss of blood or blood products in excess of 
500 mL  within any 90 day period
8.
Exposure to more than 4 new chemical entities within 12 months prior to the first 
dosing day
9.Current enrol ment or past participation within the last 30 day s before signing of 
consent in this or any  other clinical study  involving an investigational study  
treatment or an y other type of medical research 
Diagnostic assessments
10.
Presence of Hepatitis B surface antigen (HBsAg) at screening or positive Hepatitis C 
antibody  test result at screening. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
21NOTE:  Participants with positive Hepatitis C antibody  due to prior resolved diseas e can 
be enrolled, onl y if a confirmatory  negative Hepatitis C Ribonucleic acid ( RNA )test is 
obtained
11.Positive Hepatitis C RNA test result at screening or within 3 months prior to first 
dose of study  treatment
NOTE: Test is optional and participants with negative Hepatitis C antibody test are not 
required to also undergo Hepatitis C RNA testing
12.Positive human immunodeficiency  virus (HIV) antibody  test (according to local 
policies).
13.Positive drug/alcohol test at screening or on admission (Day  -1)
14.Regular us e of known drugs of abuse
Other Exclusions
15.Regular alcohol consumption within 6 months prior to the study  defined as: 
an average weekl y intake of >14 drinks for males or >7 drinks for females. One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 m L
)of beer, 5 ounces 
(150 mL) of wine or 1.5 ounces (45 m L) of 80 proof distilled spirits . 
16.Urinary  cotinine levels indicative of smoking orhistory  of regular use of tobacco -or 
nicotine -containing products within 6 months of s creening, or a total pack y ear
history  of >5 pack years.
[number of pack years = (number of cigarettes per day /20) x number of y ears 
smoked]
17.Sensitivity  to an y of the study treatments, or components thereof (including lactose 
and M agnesium St earate ), or drug or other allergy  that, in the opinion of the 
investigator or medical monitor, contraindicates participation in the study
18. Unwillingness to follow the lifesty le restrictions described in S ection 6.3.
6.3. Lifest yle Restrictions
6.3.1. Meals and Dietar y Restrictions
Participants must be willing to compl y with dieta ry and meal constraints outlined in this 
section.
While in the clinic, meals will not contain any
 of the items listed below:
-Artificial sweeteners such as mannitol, sorbitol, xylitol, Splenda or other non-
absorbable dietary  sugars
-Grapefruit or grapefruit juice and pomelos
-Apple or orange juice. Apples and oranges are permitted but not the juice of 
either. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
22-Anything from the mustard green family  (i.e., no mustard greens, kale, kohlrabi, 
broccoli , collard greens, brussel sprouts, or watercress).
-Charbroiled meats.
Participants must also abstain from eating an y of the items listed above for at least 7 
days before checking into the clinic, except there is no restriction on artificial 
sweeteners whil e the participants are outside the clinic.
Participants will fast for at least 6 hours before a fasting glucose sample is taken
(fasted at screening onl y).
On Period 1, Day 1, participants will receive a standard breakfast 2 hours before 
drug administratio n (nemiralisib). 
Participants will remain fasted until 2 hours post -
dose (nemiralisib). 
In Period 2, on all dosing day s, participants will receive a standard breakfast 1 hour 
before drug administration (itraconazole) . On Day  5, participants will remain fa sted 
until 2 hours post -dose (nemiralisib). 
At all other times, snacks and meals will be provided by  the clinical unit.  
Water will be allowed as desired except for one hour before and one hour after all 
drug administration occasions
.
6.3.2. Caffeine, A lcohol, and Tobacco
During each study  period , participants will abstain from ingesting caffeine -or 
xanthine -containing products (eg, coffee, tea, cola drinks, and chocolate) for 
24hours before the start of dosing until after collection of the fi nal pharmacokine tic 
sample.
During each study  period , participants will abstain from alcohol for 24 hours before 
the start of dosing until after collection of the final pharmacokinetic sample. 
Use of tobacco products is not allowed from 6 months prior to screening and un til 
after the final follow -up visit. 
6.3.3. Activity
Participants will abstain from strenuous exercise for 48hours before each blood 
collection for clinical laboratory  tests. Participants may  participate in light 
recreational activities only during studies .
6.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl y entered in the stud y. A minimal set of screen failure information 
is required to ensure transparent reporting of screen failu re participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities. Minimal information includes  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
23demograph y, screen failure details, eligibility  criteria, and an y serious adverse events 
(SAEs ).
Individuals who do not meet the criteria for participation in this study  (screen failure) 
may be rescreened once . Rescreened part icipants should be assigned a new participant 
number.
7. TREATMENTS
Study  treatment is defined as an y investigational treatment(s), marketed product(s), 
placebo, or medical device (s)intended to be administered to a study  participant according 
to the study  protocol.
7.1. Treatments A dministered
Study Treatment 
Name:Nemiralisib ELLIPTA Itraconazole
Dosage fo rmulation: Nemiralisib succinate blended 
with lactose and magnesium 
stearate1US sourced, commercially 
available itraconazole 
capsules
Unit dose 
strength(s)/Dosage 
level(s):100 mcg Dry Powder Inhaler 
(single-strip presentation) with 
30 doses per inhaler / 100 
mcg total dose 100 mg per capsule / 200 mg 
(2 capsules) per day 
Route of 
Administration Oral Inhalation Oral
Dosing instructions: Inhale ONCE from this 
Inhaler, as directedTo be administered with 
240mL of water and approx. 
1h after a stand ard meal.
Packaging and 
LabelingStudy Treatment will be 
provided in a foil overwrap. 
Each foil overwrap will be 
labelled as required per 
country requirement.Itraconazole will be sourced by 
the clinical site
Manufacturer GSK Itraconazole will be sourced by 
the clinical site
1. Magnesium stearate 0.4% w/w of total drug product
7.2. Dose Modification
Not applicable 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
247.3. Method of Treatment A ssignment
All participants will receive the same treatments in the periods/day s specified in Section 
5.1.
7.4. Blinding
This is an open -label study . 
7.5. Preparation/Handling/Storage/A ccountability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any discrepancies 
are reported and resolved before use of the stud y treatment.
2.Only  participants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment. All study  treatments 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.
3. The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y treatment accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).
4.Further guidance and information for the final disposition of unused study  treatment 
are provided in the Study Reference Ma nual. 
5.Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safet y risks to site staff. In the case of unintentional 
occupational exposure notify  themonitor, Medical Monitor and/or GSK study  
contact.
6.A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local la ws, or is available upon request from 
GSK.
7.6. Treatment Compliance
Participants will receive study  treatment directl y from the investigator or designee, under 
medical supervision.  The date and time of each dose administered in the clinic will be 
recorded in the source documents.  The dose of study  treatment and study  participant
identification will be confirmed at the time of dosing by  a member of the study  site staff 
other than the person administering the study  treatment.  Study  site personnel will 
examine each participant’s mouth to ensure that the study  treatment was ingested
(itraconazole onl y).
7.7. Concomitant Therapy
Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrolment or receives during the stud y must be recorded along with: 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
25reason for use
dates of administration including start and end dates
dosage information including dose and frequency
The Medical Monitor should be contacted if the re are an y questions regarding 
concomitant or prior therapy .
Participants must abstain from taking prescription or non-prescription drugs (including 
vitamins and dietary  or herbal supplements) within 14 days before the start of study  
treatment until completion of the follow- up visit, unless, in the opinion of the investigator 
and sponsor, the medication will not interfere with the study . 
Paracetamol/Acetaminophen, at doses of 2grams/day , is permitted for use any time 
during the stud y. Other concomitant m edication may  be considered on a case -by-case 
basis by  the investigator in consultation with the Medical Monitor .
7.8. Treatment after the End of the Study
Participants will not receive an y additional treatment from GSK after completion of the 
study  because onl y healthy participants are eligible for stud y participation. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
268. DISCONTINUA TION CRIT ERIA
8.1. Discontinuation of Study  Treatment
8.1.1. Liver Chemistry Stopping Criteria
Liver chemistry stopping and increased monitoring criteria have been designed to 
assure participant safety  and evaluate liver event etiology .
Study  treatment will be discontinued for a participant if liver chemistry stopping criteria 
are met:
Phase I Liver Chemistry Stopping Criteria – Liver Stopping Event Algorithm
Continue Study Treatment 
Discontinue Study Treatment  
*INR value not applicable to subjects on anticoagu lants ALT ≥3xULN No
Yes
Must  refer to Liver Safety Required Actions and Fol low up Asses sments  section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5 , if measur ed*
Liver Safet y Required Actions and F ollow up Assessments S ection can be found 
inAppendix 6.
8.1.2. QTc Stopping Criteria
A participant that meets either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from study  treatment.   
QTcF >500 msec,
Change from baseline: QTcF >60 msec
The decision to withdraw a participant willbe based on an average QTcF value of 
triplicate ECGs.  If an ECG demonstrates a prolonged QTcF, obtain 2 more ECGs over a 
brief period (5−10 minutes) , and then use the averaged QTcF values of the 3 ECGs to 
determine whether the participant should be discontinued from the study . 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
278.1.3. FEV 1stopping criteria
A participant who experiences a fall in FEV 1of 25% from baseline (screening) will be 
withdrawn from the study.  Triplicate FEV 1measurements will be taken.  The decision to 
withdraw a participant will be based on the highest of the 3 measurements.
Participants who are withdrawn and are found to have respiratory  symptoms should 
undergo approp riate diagnostic tests, to be agreed by  the investigator and sponsor 
medical monitor.
8.1.4. Other study  stopping criteria
A participant will be discontinued from the study  if they  experience a serious adverse 
event and/or unacceptable adverse events, as determin ed by  the investigator and/or 
medical monitor.  Every  effort should be made to complete safety  follow -up procedures 
after a participant is discontinued from study  drug.
The study  will be halted for an internal safet y review if there is a SAE or 2 severe AEs, 
considered to be at least possibly  related to the study  treatment (nemiralisib or 
itraconazole ).
8.1.5. Temporary  Discontinuation
A participant withdrawn from the study  treatment will no longer continue in the trial.
8.1.6. Rechallenge
8.1.6.1. Study  Treatment Restart or Re -challenge
Study  treatment restart or rechallenge after liver chemistry  stopping criteria are met by  
any participant in this study  is not allowed.
8.2. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, 
or may  be withdrawn at any  time at the discretion of the investigator for safety , 
behavioral, compliance or administrative reasons.
If the participant withdraws consent for disclosure of future information, the 
sponsor may
 retain and continue to use any  data coll ected before such a 
withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site 
study  records.
Participants who are withdrawn should complete any  safet y assessments that the 
investigator considers necessary  for the well being of the participant , and the 
assessments planned for the follow -up visit . 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
288.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repe atedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact the participant an d reschedule the missed visit 
as soon as possible and counsel the participant on the importance of maintaining 
the assigned visit schedule and ascertain whether or not the participant wishes to 
and/or should continue in the study .
Before a participant is d eemed lost to follow up, the investigator or designee 
must make every  effort to regain contact with the participant (where possible, 3 
telephone calls and, if necessary , a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact attempts should be 
documented in the participant’s medical record.
Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up. 
9. STUDY A SSESSMENTS A ND PROCEDU RES
Study  procedures and their timing are summarized in the SoA. 
Protocol waivers or exemptions are not allowed 
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if th e participant should continue or 
discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable. 
Procedures conduct ed as part of the participant’s routine clinical management (eg, 
blood count) and obtained before signing of ICF may  be utilized for screening or 
baseline purposes provided the procedure met the protocol- specified criteria and was 
performed within the time frame defined in the SoA.
The maximum amount of blood collected from each participant over the duration of 
the study , including an y extra assessments that may  be required, will not exceed 
500mL
Repeat or unscheduled samples may be taken for safet y reason s or for tec hnical 
issues with the samples.
If assessments are scheduled for the same nominal time, then the assessments should 
occur in the following order: 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
291. 12- lead ECG
2.vital signs
3.blood draws.  
Note:  The timing of the assessments should allow the blood
draw to occur at the 
exact nominal time.
9.1. Efficacy  Assessments
There will be no efficacy assessments for this study. 
9.2. Adverse Events
Planned time points for all safety  assessments are listed in the SoA (Section 2).  
Additional time points for safet y tests (such as vital signs, ph ysical exams and laboratory  
safet y tests) may be added during the course of the study based on newl y available data to 
ensure appropriate safet y monitoring.
The definitions of an AE or SA E can be found in Appendix 4 .
The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AE sthat are serious, considered related to the study treatment or the study , 
or that caused the participant to discontinue the study  treatment (see Section 8). 
9.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAE swill be collected from the signing of the ICF until the follow
-up visit
at the time points specified in the SoA (Section 2).  
All AE
swill be collected from the start of treatment until the follow -up visit at 
the time points specified in the SoA (Section 2).
Medical occurrences that begin before the start of study  treatment but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the case report form (CRF) not the AE section.
All SAE swill be recorded and reported to the sponsor or designee immediately  
and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 4 . The investigator will submit any  updated SAE data to the sponsor 
within 24 hours of it being available.
Investigators are not obligated to activel y seek AEs or SAEs in former study  
participants. However, if the investigator learns of any SAE, including a death, 
at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study  treatment or study  
participation, the investigator must promptly  notify  the sponsor. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
30The method of r ecording, evaluating, and assessing causality  of AEs and SAEs
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 4 .
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to intro duce bias when detecting AE and/or SAE. Open- ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence. 
9.2.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to pro activel y follow each 
participant at subse quent visits/contacts. All SAEs (as defined in Section 9.2), will be 
followed until the event is resolved, stabilized, otherwise explained, or the participant is 
lost to follow -up (as defined in Section 8.3). Further information on follow -up procedures 
is given in 
Appendix 4 .
9.2.4. Regulatory  Reporting Requirements for SA Es
Immediate notification by the investigator to the sponsor of a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of 
participants and the safety  of a study  treatment under clinical investigation are 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory  authority , 
Institutional Review Boards (IRB)/Independent Ethics Committees (I EC), and 
investigators.
Investigator safety
 reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local regulatory  requiremen ts and 
sponsor policy and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE or 
other specific safet y information eg, summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements.
9.2.5. Pregnancy
Details of all pregnancies infemale partners of male participants will be collected 
after the start of stud y treatment and until follow -up.
If a pregnancy  is reported, the investigator should inform GS Kwithin 24 hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 5.
Abnormal pregnancy  outcomes (eg, spontan
eous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
319.3. Treatment of Overdose
For this study , any  dose of nemiralisib greater than 100 mcg within a 24 -hour time period
will be considered an overdose.
GSK does not recommend specific treatment for an overdose of nemiralisib .The 
Investigator (or ph ysician in charge of the participant at the time) will use clinical 
judgment to treat an y overdose.
For this study , any  dose of itraconazole greater than 200 mg within a 22-hour time period 
will be considered an overdose.
GSK does not recommend specific treatment for an overdose of itraconazole . The 
Investigator (or ph ysician in charge of the participant at the time) will use clinical 
judgment and the information available in the FDA label to treat an y overdose.
In the event of an overdose, the I
nvestigator (or treating ph ysician )should:
1.Contact the Medical Monitor immediately .
2.Closely  monitor the participant for AE/SAE and laboratory  abnormalities until study  
treatment ca n no longer be detected sy stemically  (at least 14days).
3.Obtain a plasma sample for PK anal ysis within 7days from the date of the last dose 
of study  treatment if requested by  the Medical Monitor (determined on a case -by-
case basis).
4.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the CRF.
Decisions regarding dose interruptions or modifications will be made by  the investigator 
in consultation with the Medical Monitor based on the clinical evaluation of the 
participant.
9.4. Safet y Assessments
Planned time points for all safety  assessments are provided in the SoA.
9.4.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, assessments of the 
Skin, Cardiovascular , Respiratory , Gastrointestinal and Neurolog ical s ystems. 
Height and weight will also be measured and recorded at screening .
A brief ph ysical examination will include, at a minimum, assessments of the 
skin, lungs, cardiovascular s ystem, and abdomen (liver and spleen).
Investigators should pay  specia l attention to clinical signs related to previous 
serious illnesses. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
329.4.2. Vital Signs
Vital signs will be measured in a supine or semi-supine position after 5 minutes 
rest and will include temperature, sy stolic and diastolic blood pressure, and 
pulse and respir atory  rate.
For time points where vital signs are collected in triplicate, only  systolic and 
diastolic blood pressure, and pulse rate should be repeated.  There should be at 
least a 2 minute interval between readings.
Baseline will be defined as the mean o f the 3 pre -dose measurements taken on 
Day 1for each Period.
9.4.3. Electrocardiograms
12-lead ECGs will be measured in a supine or semi -supine position after 5 
minutes rest.
12-lead ECGs will be obtained at each time point during the stud y, as outlined in 
the S oA (see Section 
2).  This will be performed using an ECG machine that 
automatically  calculates the heart rate and measures PR interval, QRS duration, 
QTand QTcF intervals.  Refer to Section 8.1.2 for QTc withdrawal criteria and 
additional QTc readings that may  be necessary .
At time point sat which triplicate ECG are required, 3 individual ECG tracings 
should be obtained as clo sely as possible in succession ( no more th an 2 minutes 
apart ).  The full set of triplicates should be completed in less than 4 minutes.
9.4.4. Spirometry
Spirometry  assessments will be performed whilst the participant is in a seated 
position (if the assessment is done on a bed, the participant’s legs should be over 
the edge).
Spirometry  assessments will be repeated until 3 technicall y acceptable 
measurements have been made. The highest of the 3 values will be recorded in the 
CRF. 
Refer to Section 8.1.3. for th e FEV 1withdrawal criterion.
9.4.5. Clinical Safety  Laboratory  Assessments
Refer to 
Appendix 2for the list of clinical laboratory  tests to be performed and 
to the SoA for the timing and frequency . 
The investigator must rev iew the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the CRF. The laboratory  reports must be filed with the source
documents.
All laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or at the follow -up visit should be repeated until  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
33the values return to normal or baseline or are no longer considered significantly  
abnormal b y the investigator or medical monitor. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA.
9.5. Pharmacokinetics
A 2 mL  blood sample for PK analy sis of nemiralisib will be collected at each time -point
listed in the SoA . A 2 mL blood sample for PK analy sis of itraconazole and hy droxy -
itraconazole will be collected at each time- point listed in the SoA .  
At timepoints where nemiralisib, itraconazole and hy droxy-itraconazole are measured, a 
single 3 mL blood sample will be collected. 
The actual date and time o f each blood sample collection will be recorded.  Sample 
storage and shipping instructions will be included in the Study  reference manual ( SRM )
or equivalent.
Analy sis of plasma samples for nemiralisib will be performed within PTS -IVIVT-BIB, 
GlaxoSmithKline. Concentrations of nemiralisib will be determined in plasma samples 
using the currentl y approved bioanal ytical methodology .Raw data will be archived at 
GSK.
Analy sis of plasma samples for itraconazole and hy droxy -itraconazole will be performed 
under t he control of PTS -IVIVT-BIB/TPR GlaxoSmithKline. Concentrations of 
itraconazole and h ydrox y-itraconazole will be determined in plasma samples using the 
currentl y approved bioanalytical methodology. Raw data will be archived at the 
bioanaly tical site for a specified portion of the retention period.
9.6. Pharmacody namics
Pharmacod ynamic parameters are not evaluated in this study .
9.7. Genetics
Genetics are not evaluated in this study .
9.8. Biomarkers
Biomarkers are not evaluated in this study .
9.9. Health Economics OR Medical Resource Utilization and 
Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are 
not evaluated in this study. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
3410. STATISTICA L CONSIDER ATIONS
The primary  objective of the study  is to characterize the effect of repeat o ral dosing of 
itraconazole on the pharmacokinetics of a single inhaled dose of nemiralisib in healthy  
participants.  No formal hy potheses will be tested.
10.1. Sample Size Determination
The sample size has primarily  been based on feasibility ; however it has also been chosen 
such that the estimated level of precision achieved for AUC(0 -∞) and Cmax is considered 
to be acceptable.
Variability  estimates have been taken from preliminary  PK data (with nominal sampling 
times) for the 207674 study , since it used the sam e formulation as in this study .  The 
500mcg dose is the closest to 100mcg, so this has been chosen; indeed variability  has 
been observed to increase with dose, so this is considered a conservative estimate.
Study  207674 observed total between subject s tandard deviations (SD) on the loge scale 
of  0.382 for AUC(0 -
∞) and 0.411 for Cmax. Based on correlation observed in the 
201544 study  (rho=0.253 and 0.302 for AUC(0 -∞) and Cmax respectively ) the within 
subject SD on the loge scale has been assumed to be 0.330 for AUC(0 -∞) and 0.343 for 
Cmax for this study .
It is c onsequently  estimated that with 16 subjects providing the relevant PK parameter 
data, the upper bound of the 90% confidence interval (CI) will be within approximately  
22% of the point estimate and the lower bound within 18% for AUC(0 -∞). For Cmax 
the upper bound of the 90% CI  is estimated to be within approximately  23% of the point 
estimate and the lower bound within 19%.  The following gives the expected CI s under 
the assumption of various ratios between the two groups:
Ratio   
(nemiralisib co -administ ered with itraconazole 
/ nemiralisib administered alone)CI
AUC(0 -∞) Cmax
1 (0.82, 1.22) (0.81, 1.23)
2 (1.64, 2.44) (1.63, 2.46)
5 (4.10, 6.09) (4.07, 6.14) 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
3510.1.1. Sample Size Sensitivity
If the within subject standard deviation observed in AUC(0-∞ ) and Cmax is 10% or
20% higher than estimated, the upper and lower bounds of the 90% CI would be as 
follows: 
% increase 
in SDSD Percentage Within which the 90% CI lies
Upper bound Lower bound
AUC(0 -∞) 10% 0.3634 24% 20%
20% 0.3965 25% 20%
Cmax 10% 0.3773 27% 21%
20% 0.4116 28% 22%
10.2. Populations for A nalyses
For pur poses of analy sis, the following populations are defined:
Population Description
Screened All participants screened and for whom a record exists on the study 
database.
EnrolledAll participants who passed screening and entered the study. 
Included are: ru n-in failures and participants who took treatment.
SafetyAll participants enrolled in the study , who took at least 1 dose of 
study treatment. Participants will be analysed according to the 
treatment they actually received.
PharmacokineticAll participan ts enrolled in the study who took at least 1 dose of 
study treatment and for whom a pharmacokinetic sample was 
obtained
and analysed. Participants will be analysed according to the
treatment they received.
10.3. Statistical A nalyses
Statistical analy sis will be performed b y, or under the direct auspices of Clinical
Statistics, GlaxoSmithKline. Complete details of the planned statistical analyses will be
provided in the Reporting and Anal ysis Plan (RAP). 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
3610.3.1. Pharmacokinetic Analyses
All PK analy ses will be performed on the Pharmacokinetic Population.
Endpoint Statistical Analysis Methods
PrimaryPlasma nemiralisib concentration -time data will be analysed by non -
compartmental methods using WinNonlin. Calculations will be based on the 
actual sampling times recorded du ring the study.
From the plasma concentration-time data, the following pharmacokinetic
parameters will be determined for both Day 1 in period1 and Day 5 in period 
2, as data permit: maximum observed plasma concentration (Cmax), time to 
Cmax (Tmax), area u nder the plasma concentration -time curve [AUC(0 -t) 
and AUC(0-∞ )], terminal half life (t 1/2) and the percentage of extrapolation for 
AUC(0 -∞).
Pharmacokinetic concentration data will be presented in graphical and/or 
tabular form.
Derived pharmacokinetic p arameters will be listed [subjects with greater than 
20% extrapolated AUC (0 -∞) will be highlighted] and descriptive statistics (n, 
arithmetic mean, SD, 95% CI, minimum, median and maximum) will be 
calculated for all pharmacokinetic parameters by treatment .
In addition, for loge -transformed variables the geometric mean with 
associated 95% CI, SD on log e-scale and between subject coefficient [%CVb 
(100 * √ (exp(SD2) -1)] will be provided, where the SD is the standard 
deviation of log e transformed data.
To estimate the ratio of exposure of nemiralisib administered alone and co -
administered following repeat doses of itraconazole, mixed effects analyses 
will be performed for both log etransformed Cmax and log etransformed 
AUC(0 -∞). The geometric mean ratios wi ll be provided along with 90% 
confidence intervals and the mean squared error (MSE).
SecondaryPlasma itraconazole concentration -time data and PK parameters [Cm ax, 
Tmax, AUC(0 -t), AUC(0-∞ ) and t 1/2] for both Day 1(first dose of 
itraconazole) and Day 5 (5thDay of dosing Itraconazole or steady state) in 
period 2, will be analysed, listed and summarised as described for 
nemiralisib.  
No formal statistical analysis will occur.
10.3.2. Safety  Analyses
All safet y anal yses will be performed on the Safety  Population.  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
37Endpoint Statistical Analysis Methods
SecondaryAdverse events (AE), clinical laboratory values, vital signs, electrocardiogram
(ECG) and spirometry, will be listed and summarized by treatment.
10.3.3. Interim A nalyses
A preliminary  analy sis of PK may  be p erformed following the availability  of the PK data, 
for internal decision making. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
3811. REFERENCES
European Medicines Agency  (EMA), Guideline on the investigation of drug interactions , 
Committee for Human Medicinal Products (CHMP), 2012, CPMP/EWP/560/95/Rev. 1 
Corr. 2
GlaxoSmithKline Document Number 2012N141231_08. GSK2269557 I nvestigator’ s 
Brochure, Version 09. 13-Dec-2017.
GlaxoSmithKline Document Number 2017N345216
_00. A Mechanistic Static Model-
Based Evaluation of the Potential Magnitude of Increase in Theoph ylline Exposure 
(AUC) when co -administered with GSK2269557. 13-Dec- 2017.
Itraconazole Prescribing Information: Available at
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484S000lbl.pdf . 
Accessed 04-Dec- 2017
Ke AB, Zamek -Gliszczy nski MJ, Higg ins JW, Hall SD. I traconazole and 
Clarithromy cinas Ketoconazole Alternatives for Clinical CYP3A I nhibition Studies. 
Clinical Pharmacology & Therapeutics . 2014; 95:473 -6.
Liu L, Bello A, Dresser MJ, Heald D, Komjathy  SF, O'Mara E et al. Best practices for t he 
use of itraconazole as a replacement for ketoconazole in drug -drug interaction studies. J 
Clin Pharmacol . 2016; 56(2):143 -51
Quanjer PH, Stanojevic S; Cole T et al. Multi- ethnic reference values for spirometry for 
the 3–95- yr age range: the global lung function 2012 equations. European Respiratory  
Journal. 2012; 40: 1324–1343
U.S. Department of Health and Human Services Food and Drug Administration (FDA), 
Clinical Drug Interaction  Studies - Study Design, Data Analysis, and Clinical 
Implications, Guidance for Industry, Draft Guidance, Center for Drug Evaluation and 
Research (CDER), 2017.  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
3912. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
AE Adverse event
ALT Alanine transaminase
AST Aspartate Aminotransferase
AUC Area under the curve
BMI Body mass index
CI Confidence interval
Cmax Maximum observed plasma concentration
CONSORT Consolidated Standards of Reporting Trials
COPD Chronic obstructive pulmonary  disease
CRF Case report form
CT computerised tomography
CYP Cytochromes P450
DDI Drug drug interaction
ECG Electrocardigram
EMA European Medicines Agency
FDA Food and drug administration
FEV1 Forced expiratory  volume in 1 second
FSH Follicle stimulating hormone
FVC Forced vital capacit y
GCP Good Clinical Practice
GSK GlaxoSmithKline
HBsAg Hepatitis B surface antigen
HIV Human immunodeficiency vir us
IB Investigator’s Brochure
ICF Informed consent form
IEC Independent ethics committee
INR International normalized ratio
IRB Institutional review board
kg Killogram
mcg/ ug Microgram
mg Milligram
mL Milliliter
MSDS Material Safet y Data Sheet
MSE Mean squared error
ng Nanogram
NOAEL No observed adverse event level
PI3K Phosphoinositide 3 -kinase
PIP2 phospholipid phosphatidylinositol 4,5- biphosphate
PIP3 phosphatidy linositol 3,4 ,5-trisphosphate
PK Pharmacokinetic
QTc QT interval corrected for heart rate
QTcF QT interval corrected for heart rate b y Fridericia’s  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
40formula
RAP Reporting and anal ysis plan
RNA Ribonucleic Ac
SAE Serious adverse event
SD Standard deviation
SOA Schedule of activities
SRM Study  reference manual
SUSAR Suspected unexpected serious adverse reactions
t1/2 Half life
tmax Time to Cmax
ULN Upper limit of normal 
WOCBP Woman of childbearing potential
Trademark Information
Trademarks of the GlaxoSmi thKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
ELLIPTA WinNonlin 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
4112.2. Appendix 2: Clinical Laboratory  Tests
The tests detailed in Table 4will be performed b y the local laboratory . 
Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 6of the protocol.
Additional tests may  be performed at an y time during the stud y as determined 
necessary  by the investigator or required by  local regulations.
Table 4 Protocol -Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
Mean corpuscular 
volume Mean 
Corpuscular Hemoglobin
%Reticu locytesWhite Blood Cellcount 
with Differential :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRed Blood Cell (RBC)
Count
Hemoglobin
Hematocrit
Clinical 
Chemistry1Blood Urea 
Nitrogen ( BUN )Potassium Aspartate 
Aminotransferase
(AST) /Serum 
Glutamic- Oxaloacetic 
Transaminase (SGOT)Total and 
direct bilirubin
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic- Pyruvic 
Transaminase (SGPT)Total Protein
Glucose (fasted at 
screening only)Calcium Alkaline phosphatase
Routine 
UrinalysisSpecific gravity
pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, 
leukocyte esterase by dipstick
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsFollicle -stimulating hormone and estra diol (as needed in women of non-
childbearing potential only)
Alcohol breath test and urine drug screen (to include at minimum: 
amphetamines, barbiturates, cocaine, opiates, cannabinoids and 
benzodiazepines)
Urine cotinine
Serology (HIV antibody, hepatitis B surface antigen [HBsAg], and  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
42Laboratory 
AssessmentsParameters
hepatitis C virus antibody)
The results of each test must be entered into the CRF.
NOTES :
1. Details of liver chemistry stopping criteria and required actions and follow -up assessments after liver stopping 
or monitoring event are given in Section 8.1and Appendix 6. All events of ALT  3 × upper limit of normal 
(ULN) and bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and international normalized ratio (INR) 
>1.5, if INR measured, which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis). 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
4312.3. Appendix 3: Study  Governance Considerations
Regulatory  and Ethi cal Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Scienc es (CIOMS) International Ethical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents (eg, advertisements) must be subm itted to an I RB/IEC by  
the investigator and reviewed and approved b y the I RB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, po licies, 
and procedures established by  the IRB/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH gu idelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial info rmation as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y earafter completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the study to 
the participant or his/her legally  authorized representative and answer all 
questi ons regarding the study .  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
44Participants must be informed that their participation is voluntary . Participants 
or their legall y authorized representative will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability  and Accountability  Act (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the par ticipant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to the most current version of the ICF(s) 
during their particip ation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreened are required to sign a new ICF.
The I CF may  contain a separate section that addresses the use of remaining mandatory  
samples for optional exploratory  research in accordance with SOP- GSKF -410. The 
investigator or authorized designee will explain to each participant the objectives of the 
exploratory  research. Participants will be told that they are free to refuse to participate 
and may  withdraw their consent at any  time and for an y reason during the storage period. 
A separate signature will be required to document a participant's agreement to allow any  
remaining specimens to be used for explorat ory research. Participants who decline to 
participate will not p rovide this separate signature.
Data Protection
Participants will be assigned a unique identifier by  the sponsor. Any  participant 
records or datasets that are transferred to the sponsor will c ontain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  the sponsor in accordance wit h local data protection law. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined 
by Clinical Qualit y Assurance auditors or other authorized personnel appointed 
bythe sponsor, b y appropriate IRB/IEC members, and by  inspectors from 
regulatory  authorities.
Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
45the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. 
In accordance with standard editoria l and ethical practice, the sponsor will 
generall y support publication of multicenter studies only in their entiret y and not 
as individual site data. In this case, a coordinating investigator will be 
designated b y mutual agreement.
Authorship will be deter mined by  mutual agreement and in line with 
International Committee of Medical Journal Editors authorship requirements.
Dissemination of Clinical Study  Data
Where required b y applicable regulatory  requirements, an investigator signatory  
will be identified for the approval of the clinical study report.  The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity  to review the complete study  results at a 
GSK site or other mutually -agreeable location.
GSK will also provide the investigator with the full summary  of the stud y 
results.  The investigator is encouraged to share the summary  results with the 
study  participants, as appropriate.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with GSK 
Policy .
Data Quality  Assurance
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponso r or designee electronically  (eg, laboratory  
data). The investigator is responsible for verify ing that data entries are accurate 
and correct b y physically or electronically signing the CRF. 
The investigator must maintain accurate documentation (source dat a) that 
supports the information entered in the CRF. 
The investigator must permit study -
related monitoring, audits, IRB/IEC review, 
and regulatory  agency  inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsib le for the data management of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
and verifiable fro m source documents; that the safety  and rights of participants 
are being protected; and that the study is being conducted in accordance with the  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
46currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this 
study  must be retained by the investigator for 25years from the issue of the final 
Clinical Study  Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may  be 
destroy ed during the retention period without the written approval of the 
sponsor. No records may be transferred to another location or part y without 
written notification to the sponsor. 
Sourc e Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcr ibed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may  need to request previous 
medical records or transfer records, depending on the study . Also, current 
medical records must be available.
Definition of what constitutes source data can be found in the Data Entry  
Tracking Guidelines or equivalent document .
Study and Site Closure
GSK or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of GSK. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investig ator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants b y the investigator
Discontinuation of fur ther study  treatment development 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
4712.4. Appendix 4: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally
associated with the use of a study treatment, whether or not considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) t emporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs measurem ents), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent pre- existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clini cal sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdo se taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are a ssociated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and /or  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
48convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
Definition of SA E
If an event is not an AE per definition above, th en it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Islife-threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay ) at the hospital or emergency  ward for o bservation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospitalization are AE. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary , the AE 
should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as u ncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Othe r situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospitalization but ma y 
jeopardize the participant or may require medical or surgical intervention to prevent  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
49one of the other outcomes listed in the above definition. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse.
Recording A E and SA E
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory, and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to GSK in lieu of completion of the GSK /AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y GSK . In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to GSK .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during t he stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interf eres with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE ca n be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
50Assessment of Causality
The investigator is obligated to assess the relationship between study  treatment and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out .
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he /she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to GSK . However, it is very 
important that the inve stigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to GSK .
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  GSK to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide GSK with a cop y of an y post-mortem 
findings including histopathology .
New or updated infor mation will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to GSK within 24 hours of 
receipt of the information. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
51Reporting of SA E to GSK
SAE Reporting to GSK via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the SAE coordinator .
In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by 
overnight ma il or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time 
frames.
Contacts for SAE reporting can be found in the SRM. 2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
5212.5. Appendix 5: Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below)
Women in the follow ing categories are not considered WOCBP
1.Premenarchal
2. P remenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpingectomy
Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: revie w of participant’s 
medical records, medical examination, or medical history  interview.
3. P ostmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Female s on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during the stud y. Otherwise, they must discontinue HRT 
to allow confirmation of postm enopausal status before stud y enro lment.
Contraception Guidance
Male participants
Male participants with female partners of child- bearing potential are eligible to 
participate if they  agree to ONE of the following during the protocol -defined 
time frame in Section 6.1 : 
Are abstinent from penile -vaginal intercourse as their usual and preferred 
lifesty le (abstinent on a long term and persistent basis) and agree to remain 
abstinent  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
53Agree to use a male condom plus an additional method of contraception 
with a failure rate of <1% per year as described in Table 5 when having 
penile -
vaginal intercourse with a woman of childbearing potential 
Men with a pregnant or breastfeeding partner must agr ee to remain abstinent 
from penile -vaginal intercourse or use a male condom during each episode of 
penile penetration during the protocol -defined time frame .
In addition, male participants must refrain from donating sperm for duration of 
study  and for at l east 10 day safter thelast dose .
Table 5
Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrog en-and progestogen -containing) hormonal contraception associated with 
inhibition of ovulation
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulation
injectable 
Highly Effective Methods That Are U ser Independent 
Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulation
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
bilateral tubal occlusion / ligation
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.) 
Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs t o be evaluated in relation to the duration of the study and 
the preferred and usual lifestyle of the participant.)
NOTES: 
a. Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulatio ns regarding the use of contraceptive methods for participants in clinical studies.  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
54Collection of Pregnancy  Information
Male participants with partners who become pregnant
Investigator will attempt to collect pregnancy  information on any  male participant ’s 
female partner of a male study  participant who becomes pregnant while participating 
in this study . This applies only  to participants who receive study  treatment.
After obtaining the necessary  signed informed consent from the pregnant female 
partner dire ctly, the investigator will record pregnancy information on the 
appropriate form and submit it to GSK within 24 hours of learning of the partner’s 
pregnancy . 
Partner will also be followed to determine the outcome of the pregnancy . 
Information on the statu s of the mother and child will be forwarded to GSK
Generally , follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date. An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalie s) or indication for procedure.  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
5512.6. Appendix 6: Liver Safety : Required A ctions and Follow -up 
Assessments 
Phase I liver chemistry stopping criteria and required follow up assessments
Liver Chemistry Stopping Criteria 
ALT- absoluteALT≥3xULN
If ALT ≥3xULN AND bilirubin1,22xULN (>35% direct bilirubin) or  INR>1.5, 
Report as an SAE.
See additional Actions and Follow Up Assessments listed below
Required Actions and Follow up Assessments 
Actions Follow Up Assessments
Immediately discontinue study treatment
Report the event to GSK within 24 hours
Complete the liver event CRF, and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until l iver chemistries 
resolve, stabilise, or return to within baseline 
(see MONITORING below)
MONITORING:
If ALT ≥3xULN AND bilirubin 2xULN  or INR 
>1.5
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24 
hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabili se or return to 
within baseline
A specialist or hepatology consultation is 
recommended
If ALT ≥3xULN AND bilirubin <2xULN  and INR 
≤1.5:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform Viral hepatitis serology3
Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward 
trend
Obtain blood sample for pharmacokinetic 
(PK) analysis, obtained within 7 days of 
last dose4 
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to a ssess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form 
including acetaminophen, herbal remedies , 
other over the counter medications.
Record alcohol use on the liver event 
alcohol intake case report form
If ALT ≥3xULN AND bilirubin 2xULN  or INR 
>1.5 :
Anti-nuclear antibody, anti -smooth muscle  2018N365720_00
2017N347248_00 CONFIDENTIA L
206874
56Liver Chemistry Stopping Criteria 
liver event follow up assessmen ts within 24-
72 hrs
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within baselineantibody, Type 1 anti -liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins.
Serum acetaminophen adduct high 
performanc e liquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophen contribution to liver injury 
in subjects with definite or likely 
acetaminophen use in the preceding week 
[James, 2009].
Liver imaging (ultrasound , magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractiona tion is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN and bilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin on 
dipstick, indicati ng direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, if INR 
measured, which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated will 
not apply to subjects receiving anticoagulants
3. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
4. PK sample may not be required for subjects known to be receiving placebo or non -GSK comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
PK blood sample draw on the CRF. If the date or time of the last dose is unc lear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are in 
the SRM .
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784. 2018N365720_00